{
    "clinical_study": {
        "@rank": "116097", 
        "arm_group": {
            "arm_group_label": "Nimotuzumab & nab-paclitaxel & cisplatin", 
            "arm_group_type": "Experimental", 
            "description": "Nimotuzumab: 200mg,IV once a week during chemotherapy.\nNab-paclitaxel: 125mg/m2,(IV over 30 min) (days 1 and 8) on 21 day cycle\nCisplatin: 75mg/m2,IV on 21 day cycle"
        }, 
        "brief_summary": {
            "textblock": "There have been reports suggesting that anti-epidermal growth factor antibody nimotuzumab is\n      advantageous for advanced esophageal cancer patients in combination with chemotherapy or\n      radiotherapy.And,albumin-bound paclitaxel was characterized with high tolerated doses with\n      greater efficacy,and with greater concentration in tumor tissue compared with normal\n      tissues.So,The objective of this single-arm phase II trial was to evaluate the benefit of\n      nimotuzumab plus nab-paclitaxel and cisplatin in patients with advanced esophageal\n      carcinoma."
        }, 
        "brief_title": "Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Stage IV Esophageal Squamous Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Esophageal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "In the past decade, clinical trials have evaluated the role of chemotherapy, radiation, or\n      both, for patients with advanced esophageal carcinoma, but have all failed to demonstrate a\n      consistent survival benefit. In Eastern countries, Chemotherapy became one of the treatment\n      strategies for advanced esophageal cancer. In an effort to improve the efficacy of systemic\n      chemotherapy, the investigators conducted a prospective study to evaluate the regimen of\n      Nimotuzumab plus Nab-paclitaxel/cisplatin for patients with advanced esophageal squamous\n      cell carcinoma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient who was confirmed stage IV esophageal carcinoma by pathologic histology or\n             cytology.\n\n          -  Males or females aged \u226518 years, < 75 years.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n\n          -  Life expectancy \u226512 weeks.\n\n          -  Adequate bone marrow, renal, and liver function are required.\n\n          -  Able to comply with the required protocol and follow-up procedures, and able to\n             receive oral medications.\n\n        Exclusion Criteria:\n\n          -  Any unstable systemic disease (including active infection, uncontrolled hypertension,\n             unstable angina, congestive heart failure, myocardial infarction within the previous\n             year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic\n             disease).\n\n          -  Allergy to anti-EGFR antibody.\n\n          -  Female subjects should not be pregnant or breast-feeding.\n\n          -  Adequate hematological function: Absolute neutrophil count (ANC) \u22651.5 x 109/L, and\n             Platelet count \u2265100 x 109/L. Adequate renal function: Serum creatinine \u2264 1.5 x ULN,\n             or \u2265 50 ml/min. Adequate liver function: total bilirubin < 1.5 x upper limit of\n             normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST)\n             < 2.5 x ULN in the absence of liver metastases, or < 5 x ULN in case of liver\n             metastases.\n\n          -  Patient assessed by the investigator to be unable or unwilling to comply with the\n             requirements of the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034968", 
            "org_study_id": "ZYTOP1406"
        }, 
        "intervention": {
            "arm_group_label": "Nimotuzumab & nab-paclitaxel & cisplatin", 
            "description": "Nimotuzumab: 200mg,IV once a week during chemotherapy.", 
            "intervention_name": "Nimotuzumab", 
            "intervention_type": "Drug", 
            "other_name": "Anti epidermal growth factor receptor antibody h-R3"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Nimotuzumab", 
            "Nab-Paclitaxel", 
            "Carcinoma of Esophagus"
        ], 
        "lastchanged_date": "January 13, 2014", 
        "location": {
            "contact": {
                "email": "doczq.2008@gmail.com", 
                "last_name": "Qiong Zhao, MD", 
                "phone": "0571-87236802"
            }, 
            "facility": {
                "address": {
                    "city": "Hangzhou", 
                    "country": "China", 
                    "state": "Zhejiang", 
                    "zip": "310003"
                }, 
                "name": "The first affiliated hospital, Zhejiang University"
            }, 
            "investigator": {
                "last_name": "Qiong Zhao, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma", 
        "other_outcome": [
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Adverse events were classified according to U.S. National Cancer Institute common toxicity criteria, version 4.0", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "During the chemotherapy,an expected average of 3 weeks"
            }
        ], 
        "overall_contact": {
            "email": "doczq.2008@gmail.com", 
            "last_name": "Qiong Zhao, MD", 
            "phone": "0571-87236802"
        }, 
        "overall_official": {
            "affiliation": "The first affiliated hospital, Zhejiang University", 
            "last_name": "Qiong Zhao, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival(PFS)", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034968"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zhejiang University", 
            "investigator_full_name": "Qiong Zhao", 
            "investigator_title": "Chief of Department of Thoracic Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Objective Response Rate", 
            "safety_issue": "No", 
            "time_frame": "From date of treatment until the date of progression, assessed up to 2 months"
        }, 
        "source": "Zhejiang University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhejiang University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}